Reviewer: WANG Ning-xia, Literature Co-worker: ZHANG Yi-fang. PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib （BUP） Plus Fulvestrant （FULV） in Breast Cancer Patient with Aromatase Inhibitors[J]. Journal of Evidence-Based Medicine, 2016, 16(3): 149-151. DOI: 10.12019/j.issn.1671-5144.2016.03.008
|
Citation:
|
Reviewer: WANG Ning-xia, Literature Co-worker: ZHANG Yi-fang. PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib （BUP） Plus Fulvestrant （FULV） in Breast Cancer Patient with Aromatase Inhibitors[J]. Journal of Evidence-Based Medicine, 2016, 16(3): 149-151. DOI: 10.12019/j.issn.1671-5144.2016.03.008
|
Reviewer: WANG Ning-xia, Literature Co-worker: ZHANG Yi-fang. PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib （BUP） Plus Fulvestrant （FULV） in Breast Cancer Patient with Aromatase Inhibitors[J]. Journal of Evidence-Based Medicine, 2016, 16(3): 149-151. DOI: 10.12019/j.issn.1671-5144.2016.03.008
|
Citation:
|
Reviewer: WANG Ning-xia, Literature Co-worker: ZHANG Yi-fang. PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib （BUP） Plus Fulvestrant （FULV） in Breast Cancer Patient with Aromatase Inhibitors[J]. Journal of Evidence-Based Medicine, 2016, 16(3): 149-151. DOI: 10.12019/j.issn.1671-5144.2016.03.008
|
DownLoad: